DGX

NYSE

QUEST DIAGNOSTICS INC

Latest disclosureOctober 2, 2026

Insider score Why 0?: 0/ 100
Qualifying buys · 30d: $0

0 purchases · 7 sales

Price by TradingView

Insider transactions 42

Limited filing history

Filters

Last 30 daysNo qualifying insider buying. No qualifying insider sales.

Showing the first 6 of 7 trades on this page.

Sale disclosed

J. E. Davis

CEO and President

Common Stock

Reported value: $2.43M
Reported price: $242.72 / share

Sale disclosed

Michael E. Prevoznik

SVP & General Counsel

Common Stock

Reported value: $3.89M
Reported price: $242.8755 / share

Sale disclosed

Michael E. Prevoznik

SVP & General Counsel

Common Stock

Reported value: $1.52M
Reported price: $243.6275 / share

Sale disclosed

Michael E. Prevoznik

SVP & General Counsel

Common Stock

Reported value: $105.14K
Reported price: $244.5148 / share

Sale disclosed

Mark E. Delaney

SVP & Chief Commercial Officer

Common Stock

Reported value: $376.29K
Reported price: $235.18 / share

Sale disclosed

Karthik Kuppusamy

SVP, Clinical Solutions

Common Stock

Reported value: $1.63M
Reported price: $200.00 / share

Sale disclosed

J. E. Davis

CEO and President

Common Stock

Reported value: $1.94M
Reported price: $194.14 / share

Reporting insider	Security / transaction	Amount / price	Value	Traded / disclosed	Source
CEO and President	Common StockSale10b5-1	10,000$242.72 / share	$2.43M	Sep 1Filed Sep 3 · 2d later	SEC filing
SVP & General Counsel	Common StockSale10b5-13 trades	22,677avg $243.11 / share	$5.51M	Aug 28Filed Aug 31 · 3d later	3 filings 16,010 @ $242.88 · $3.89MSEC filing 6,237 @ $243.63 · $1.52MSEC filing 430 @ $244.51 · $105.14KSEC filing
SVP & Chief Commercial Officer	Common StockSale10b5-1	1,600$235.18 / share	$376.29K	Jul 28Filed Jul 29 · 1d later	SEC filing
SVP, Clinical Solutions	Common StockSale10b5-1	8,147$200.00 / share	$1.63M	Jun 4Filed Jun 8 · 4d later	SEC filing
CEO and President	Common StockSale10b5-1	10,000$194.14 / share	$1.94M	Jun 1Filed Jun 2 · 1d later	SEC filing

Congress transactions 8

All Congress filings

Sale disclosedAmended report

Quest Diagnostics Incorporated Common Stock (DGX) · Stock

The filing reports a sale for a spouse.

Carol Devine MillerReporting House member

Reported amount: $15,001 – $50,000Reported range; exact amount not disclosed.
Trade date: March 10, 2025

Sale disclosedAmended report

Quest Diagnostics Incorporated Common Stock (DGX) · Stock

The filing reports a sale for a joint account.

Julie JohnsonReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: October 30, 2025

Purchase disclosedAmended report

Quest Diagnostics Incorporated Common Stock (DGX) · Stock

The filing reports a purchase for a joint account.

Julie JohnsonReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: October 30, 2025

Purchase disclosed

Quest Diagnostics Incorporated Common Stock · Stock

The filing reports a purchase for the member.

AAAlan ArmstrongReporting Senate member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: March 30, 2026

Purchase disclosed

Quest Diagnostics Incorporated Common Stock · Stock

The filing reports a purchase for the member.

AAAlan ArmstrongReporting Senate member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: March 27, 2026

Sale disclosed

Quest Diagnostics Incorporated Common Stock (DGX) · Stock

The filing reports a sale for the member.

Julia LetlowReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: July 24, 2025

Purchase disclosed

Quest Diagnostics Incorporated Common Stock (DGX) · Stock

The filing reports a purchase for the member.

Julia LetlowReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: April 28, 2025

Sale disclosed

Quest Diagnostics Incorporated Common Stock (DGX) · Stock

The filing reports a sale for a joint account.

Julie JohnsonReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: November 3, 2025

Why this buying score?

No qualifying common-equity purchases

No eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.

+0 pts

This score describes qualifying insider purchases at issuer level. Read the methodology

Sources and coverage

Limited filing history · Market-wide discovery does not establish complete company history. View coverage

Source: SEC EDGAR · Form 4
Issuer CIK: 0001022079
Latest public acceptance: Oct 2, 2026, 08:33 PM UTC
Score calculated: Oct 7, 2026, 12:06 AM UTC
Parser: form4-parser-1.5
Classifier: form4-classifier-1.1
Scoring methodology: insider-experimental-1.1
Availability: Public filing time, not trade date

Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.

Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.

Reporting insider

Security / transaction

Amount / price

Value

Traded / disclosed

Source

CEO and President

Common StockSale10b5-1

10,000$242.72 / share

$2.43M

Sep 1Filed Sep 3 · 2d later

SEC filing

SVP & General Counsel

Common StockSale10b5-13 trades

22,677avg $243.11 / share

$5.51M

Aug 28Filed Aug 31 · 3d later

3 filings

16,010 @ $242.88 · $3.89MSEC filing
6,237 @ $243.63 · $1.52MSEC filing
430 @ $244.51 · $105.14KSEC filing

SVP & Chief Commercial Officer

Common StockSale10b5-1

1,600$235.18 / share

$376.29K

Jul 28Filed Jul 29 · 1d later

SEC filing

SVP, Clinical Solutions

Common StockSale10b5-1

8,147$200.00 / share

$1.63M

Jun 4Filed Jun 8 · 4d later

SEC filing

CEO and President

Common StockSale10b5-1

10,000$194.14 / share

$1.94M

Jun 1Filed Jun 2 · 1d later

SEC filing

Why this buying score?

No qualifying common-equity purchases

No eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.

+0 pts

This score describes qualifying insider purchases at issuer level. Read the methodology

Sources and coverage

Limited filing history · Market-wide discovery does not establish complete company history. View coverage

Source: SEC EDGAR · Form 4
Issuer CIK: 0001022079
Latest public acceptance: Oct 2, 2026, 08:33 PM UTC
Score calculated: Oct 7, 2026, 12:06 AM UTC
Parser: form4-parser-1.5
Classifier: form4-classifier-1.1
Scoring methodology: insider-experimental-1.1
Availability: Public filing time, not trade date

Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.